← Every company
Pfizer Inc Patents
What Pfizer Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
PFE on carbonthat →Filings on file
57
Granted
0
Still pending
57
Filed under
2 names
57 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| Preparation Of A Pyrimidinyl-3,8-Diazabicyclo[3.2.1]Octanylmethanone Derivative And Salt ThereofC07D 487/08Filed as PFIZER INC.2026-04-20Adam Edward GOETZ | pending |
| COMPOSITIONS AND METHODS FOR TREATMENT OF ABNORMAL CELL GROWTHA61K 9/2027, A61K 9/2054, A61P 43/00, A61P 11/00, A61P 15/00, A61P 35/00, A61K 9/1635, A61K 9/1641, A61K 9/2018, A61K 9/2031, A61K 9/2059, A61K 9/2095, A61K 31/506, A61K 45/06Filed as Pfizer Inc.2026-04-17Mahesh Padval | pending |
| COMPOUNDS FOR THE ACTIVATION OF AMPKC07D 471/04, A61P 9/00, A61K 31/444, A61K 31/4545, A61K 31/4725, A61K 31/4985, A61K 31/501, A61K 31/519, A61K 31/5377, A61K 45/06, C07D 401/14, C07D 498/08, C07D 519/00Filed as Pfizer Inc.2026-04-10Gary Erik ASPNES | pending |
| IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINESA61K 39/092, A61K 47/50, A61K 47/646, A61K 47/6415, A61P 31/00, A61P 31/04, A61K 39/385, A61K2039/6031, A61K2039/6037, A61K2039/70Filed as Pfizer Inc.2026-04-09Annaliesa Sybil Anderson | pending |
| Combinations Comprising Benzodioxol as GLP-1R Agonists for Use in the Treatment of NASH/NAFLD and Related DiseasesA61P 3/10, A61K 31/438, A61P 1/16, A61P 3/04, A61K 31/444, A61K 31/454, A61K 31/4545, A61K 31/46, A61K 31/496, A61K 31/506, A61K 31/5377, A61K 38/1709, A61K 38/1796, A61K 38/26, A61K 38/28, A61K 45/06, A61K2300/00Filed as Pfizer Inc.2026-03-20Gary E. Aspnes | pending |
| Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses ThereofA61K 47/646, A61K 39/092, A61K 47/6415, Y02A 50/30, A61P 31/04, A61K2039/54, A61K2039/545, A61K2039/55505, A61K2039/575, A61K2039/6037, A61K2039/70Filed as Pfizer Inc.2026-03-20Emilio Anthony Emini | pending |
| SUBSTITUTED PYRIDINONE COMPOUNDS AND USES THEREOFA61K 31/437, C07D 471/04, A61P 3/00, A61P 9/00, A61K 31/444, A61K 31/497, A61K 31/506, A61K 31/522, A61K 31/5377, C07D 473/30Filed as Pfizer Inc.2026-03-13John Marion Curto | pending |
| SUBSTITUTED PYRIDINONE COMPOUNDS AND USES THEREOFFiled as Pfizer Inc.2026-03-03John Marion Curto | pending |
| PROLINE DERIVATIVES AND USES THEREOFC07D 401/14, C07D 417/12, A61K 31/427, A61K 31/4439, C07D 401/12Filed as Pfizer Inc.2026-02-23Kevin James Filipski | pending |
| DLL3 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTSC07K 14/705, C07K 16/28, C07K 16/2809, A61P 35/00, A61K2239/55, A61K2239/31, A61K2239/38, A61K 40/42, A61K 40/4204, A61K 40/4202, A61K 40/31, A61K 40/11, A61K2039/505, A61K2121/00, A61K2300/00, C07K 14/7051, C07K 14/70578, C07K 14/70596, C07K 16/18, C07K 16/2887, C07K2317/24, C07K2317/565, C07K2317/622, C07K2319/03, C07K2319/33, C07K2319/70, C12N 5/0636, C12N 15/63, C12N2510/00Filed as Pfizer Inc.2026-02-23Yi ZHANG | pending |
| COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND KAT6 INHIBITORSFiled as PFIZER INC.2026-02-04NATASHA FARROKH HOMJI MISHRA | pending |
| DNA PLASMIDSFiled as PFIZER INC.2026-02-02DANIEL WARD ALLISON | pending |
| SULFUR-CONTAINING HETEROCYCLOALKYL SUBSTITUTED BICYCLIC COMPOUNDSFiled as PFIZER INC.2026-01-13IAN BROOKS PERRY | pending |
| HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDSC07D 401/14, A61P 25/14, A61P 27/02, A61P 7/00, A61P 37/02, A61P 9/10, A61P 25/28, A61P 25/30, A61P 25/22, A61P 3/04, A61P 3/06, A61P 25/04, A61P 3/10, A61P 7/12, A61P 9/12, A61P 13/12, A61P 25/18, A61P 25/24, A61P 31/04, A61P 9/04, A61P 25/00, A61P 25/16, A61P 3/12, A61P 25/06, A61K 31/444, A61K 31/501, A61K 31/506, A61K 31/513, C07D 401/12, C07D 403/12, C07D 405/14Filed as Pfizer Inc.2025-12-29Michael Aaron Brodney | pending |
| METHODS AND COMPOSITIONS FOR CANCER TREATMENTA61K 39/395, C07K 16/2878, A61P 35/02, A61P 35/00, A61K 31/138, A61K 31/167, A61K 31/573, A61K2039/507, A61K2039/545, C07K 16/248, C07K 16/2809, C07K 16/283, C07K 16/2863, C07K 16/2896, C07K2317/24, C07K2317/31, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/71Filed as PFIZER INC.2025-12-19Erica Ehrha PARK | pending |
| SOLID FORMS OF (R)-N-(3-(7-METHYL-1H-INDAZOL-5-YL)-1-(4-(1-METHYLPIPERIDIN-4-YL)PIPERAZIN-1-YL)-1-OXOPROPAN-2-YL)-4-(2-OXO-1,2-DIHYDROQUINOLIN-3-YL)PIPERIDINE-1-CARBOXAMIDEC07D 401/14, A61K 31/496, C07B2200/13Filed as Pfizer Inc.2025-12-18Jake Dengelegi | pending |
| IMMUNOGENIC COMPOSITIONS AND USES THEREOFA61K 39/092, A61K 39/385, A61P 37/04, A61P 1/16, A61P 9/00, A61P 3/04, A61P 31/18, A61P 3/10, A61P 31/04, A61P 35/00, A61K 39/39, A61K2039/545, A61K2039/55, A61K2039/55505, A61K2039/6031, A61K2039/6037, A61K2039/6068, A61K2039/70Filed as Pfizer Inc.2025-12-17Annaliesa Sybil Anderson | pending |
| IMMUNOGENIC COMPOSITIONS AND USES THEREOFA61K 39/0258, A61P 37/04, A61P 31/04, A61K2039/53, A61K2039/55555, A61K2039/575, A61K2039/70Filed as Pfizer Inc.2025-12-16Robert George Konrad Donald | pending |
| METHOD OF CELL CULTUREC12N 5/0018, C12N 5/0682, C12N2500/32, C12N2500/33, C12N2500/34, C12N2500/60, C12N2501/80, C12N2501/999, C12N2510/02Filed as Pfizer Inc.2025-12-09Gregory Walter Hiller | pending |
| Process and Intermediates for Preparing IbuzatrelvirC07D 207/26, C07D 207/16Filed as Pfizer Inc.2025-12-08Christophe Philippe Allais | pending |
| METHODS AND MODIFIED DOSING REGIMENS COMPRISING A CDK4 INHIBITOR FOR THE TREATMENT OF CANCERA61K 31/506, A61P 35/00, A61K 31/565Filed as PFIZER INC.2025-12-01Justin Thomas HOFFMAN | pending |
| COMPOSITIONS COMPRISING THREE OSPA FUSION PROTEINS FOR MEDICAL USEA61P 31/04, A61K 39/0225, A61P 31/00, A61P 37/04, Y02A 50/30, A61K2039/545, A61K2039/55505, A61K2039/6018, A61K2039/70, C07K 14/20, C07K2319/00Filed as Pfizer Inc.2025-11-26Nicole Bézay | pending |
| IMMUNOGENIC COMPOSITIONS AND USES THEREOFFiled as Pfizer Inc.2025-11-25Robert George Konrad Donald | pending |
| COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CDK4 INHIBITORSA61K 31/496, A61P 35/04, A61P 35/00, A61K 31/506Filed as PFIZER INC.2025-11-25Sudhakar Reddy CHINTHARLAPALLI | pending |
| ANTI-TL1A ANTIBODY THERAPEUTIC METHODSC07K 16/2875, C12Q 1/6883, C12Q 1/6886, A61P 1/00, A61K 9/0019, A61K 45/06, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/565, C12Q 1/6827, C12Q 1/6874, C12Q 1/689, C12Q2563/107, C12Q2600/106, C12Q2600/156, C12Q2600/172Filed as Pfizer Inc.2025-11-14Sudhir PENUGONDA | pending |
| Biaryl Acid CompoundsC07D 487/04, A61P 35/00, A61K 31/437, A61K 31/444, A61K 31/506, A61K 31/519, A61K 45/06, C07D 401/14, C07D 471/04Filed as Pfizer Inc.2025-11-14James Lester COLLINS III | pending |
| Biaryl Acid CompoundsFiled as Pfizer Inc.2025-11-03James Lester COLLINS III | pending |
| THERAPEUTIC ANTIBODIES AND THEIR USESFiled as PFIZER INC.2025-10-31Tracy Chia-Chien KUO | pending |
| TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOFFiled as Pfizer Inc.2025-10-28Debra Pittman | pending |
| LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOFC07D 471/04, A61P 37/00, A61P 37/04, A61P 35/00, A61K 9/1277, A61K 31/4745, A61K 31/496, A61K 39/092, A61K2039/55555, A61K2039/6037Filed as Pfizer Inc.2025-10-23Derek William Bartlett | pending |
| LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOFA61K 39/0258, C07D 471/04, A61P 37/00, A61P 37/04, A61P 35/00, A61K 39/39, A61K2039/53, A61K2039/55555, A61K2039/55577Filed as Pfizer Inc.2025-10-23Derek William Bartlett | pending |
| Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereofA61K 39/092, A61P 31/04, A61K 39/385, A61K2039/55544, A61K2039/6037, A61K2039/627, C08B 37/006Filed as Pfizer Inc.2025-10-21Kaushik DUTTA | pending |
| METHODS OF TREATING HEPATIC-ONLY METASTATIC UVEAL MELANOMAA61K 31/497, A61P 35/04, A61K 31/4545Filed as PFIZER INC.2025-10-17MATTHEW ANTHONY MAURER | pending |
| VARENICLINE FORMULATIONSA61P 25/34, A61K 9/2013, A61K 9/2009, A61K 9/2054, A61K 9/282, A61K 9/2893, A61K 31/55, A61K 47/14Filed as Pfizer Inc.2025-10-17Alan Francis CARMODY | pending |
| PYRIDO[4,3-D]PYRIMIDINE COMPOUNDSA61K 31/553, C07D 519/00, A61P 35/00, A61K 31/519, A61K 45/06Filed as Pfizer Inc.2025-10-16Jacob Cole DEFOREST | pending |
| Pyrido[4,3-d]pyrimidine CompoundsC07D 519/00, A61P 35/00, A61K 31/553Filed as Pfizer Inc.2025-10-07Benjamin Joseph BURKE | pending |
| METHOD OF FORMING MULTI-SPECIFIC ANTIBODIES FROM HOMODIMER ANTIBODIES AND PHARMACEUTICAL PRODUCT INCLUDING MULTI-SPECIFIC ANTIBODIES THUS OBTAINEDC07K 1/1075, C07K 16/065, C07K 1/042, C07K 1/10, C07K2317/31Filed as Pfizer Inc.2025-10-06Verzhiniya AHO | pending |
| EXTENDED RELEASE FORMULATIONS COMPRISING SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOFA61K 31/416, A61P 37/06, A61P 1/00, A61P 29/00, A61K 9/0053, A61K 9/5015, A61K 9/5026, A61K 31/405, A61K 31/4184, A61K 31/425, A61K 31/427, A61K 31/437, A61K 31/4439, A61K 31/7056Filed as Pfizer Inc.2025-10-03Alfred Berchielli | pending |
| KAT6A AS A PREDICTIVE BIOMARKER FOR TREATMENT OF BREAST CANCER WITH A CDK4 INHIBITOR AND AN ANTIESTROGEN AND METHODS OF TREATMENT THEREOFG01N 33/57515, A61K 31/4196, A61K 31/506, A61K 31/519, A61K 31/565, A61K 45/06, C12Q 1/6886, C12Q2600/106, C12Q2600/158, G01N2800/52, A61K2300/00Filed as PFIZER INC.2025-09-29Shibing DENG | pending |
| COMPOSITIONS AND METHODS FOR REDUCTION OF DOUBLE-STRANDED RNAFiled as PFIZER INC.2025-09-25NIKHIL CHANDRAKANT ADI | pending |
| BCKDK INHIBITORS AND/OR DEGRADERSC07D 333/68, C07D 333/70, A61P 1/16, A61P 9/00, A61P 3/04, A61P 3/10, A61P 13/12, A61P 9/04, A61P 35/00, A61K 31/381, A61K 45/06, A61K2300/00, C07B2200/13, C07D 307/85, C07D 409/04Filed as Pfizer Inc.2025-09-24Leanne Marie BUZON | pending |
| LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOFFiled as Pfizer Inc.2025-09-23Derek William Bartlett | pending |
| LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOFFiled as Pfizer Inc.2025-09-23Derek William Bartlett | pending |
| MEDIA AND FERMENTATION METHODS FOR PRODUCING POLYSACCHARIDES IN BACTERIAL CELL CULTUREC12N 1/20, Y02A 50/30, C12N 1/205, C12R2001/46, C12P 19/04Filed as Pfizer Inc.2025-09-16Sunil Gururao Desai | pending |
| Modulating the Innate Immunity of RNAA61K 9/5123, A61K 39/145, A61K 9/0019, A61K 9/1272, A61K 31/4725, A61K 31/517, A61K 31/7105, A61K 31/713, A61K2039/53, A61K2039/55555, A61K2039/70, C12N 7/00, C12N 15/67, C12N 15/88, C12N2760/16134, A61K2300/00Filed as Pfizer Inc.2025-09-15Pirada Suphaphiphat Allen | pending |
| HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDEA61K 39/12, A61K 39/245, C07K 14/005, A61P 31/22, C07K 14/045, C12N 7/00, C12N2710/16122, C12N2710/16134Filed as Pfizer Inc.2025-09-12Yuhang Liu | pending |
| HYBRID SENSOR NETWORK IN AUTOCLAVING OF PRE-FILLED VIALSG06F 30/20, G06F2119/14Filed as Pfizer Inc.2025-09-09Kirk ROFFI | pending |
| SYSTEMS AND METHODS FOR REDUCING ELECTROSTATIC FORCE IN DYNAMIC FREEZE DRYINGFiled as Pfizer Inc.2025-09-02Matthias PLITZKO | pending |
| DYNAMIC BULK FREEZE DRYING DEVICES AND METHODSFiled as Pfizer Inc.2025-09-02Wolfgang BUERGELIN | pending |
| SYSTEMS AND METHODS FOR PRE-CONDITIONING FROZEN BULK IN DYNAMIC BULK FREEZE DRYINGF26B 5/06, F26B 5/065Filed as Pfizer Inc.2025-09-02Bernhard LUY | pending |
| SYSTEMS AND METHODS FOR ANNEALING FROZEN BULK IN DYNAMIC BULK FREEZE DRYINGF26B 5/06, F26B 3/24, F26B 5/042, F26B 11/04, F26B 25/16Filed as Pfizer Inc.2025-09-02Matthias PLITZKO | pending |
| METHODS FOR TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE WITH AN ANTI-TL1A ANTIBODYFiled as Pfizer Inc.2025-08-26Rhian Catrin JACOB-MOFFATT | pending |
| INJECTION DEVICE WITH AN IMPROVED TRIGGERING MECHANISMA61M 5/2033, A61M 5/31501, A61M 5/31566, A61M 5/31578, A61M 5/3202, A61M 5/3245, A61M2005/2013, A61M2005/208, A61M2005/31508, A61M2005/3247Filed as Pfizer Inc.2025-08-21Christopher William Chudek | pending |
| GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOFC07D 207/16, A61P 3/04, A61P 3/10, A61K 31/401, A61K 31/445, C07B2200/05, C07D 211/60, C07D 401/12Filed as Pfizer Inc.2025-08-20Kevin James Filipski | pending |
| SYRINGE WITH A SILICONE-LUBRIFIED SURFACE, LUBRIFIED PLUNGER FOR SUCH SYRINGE AND RELATED METHOD OF LUBRIFYINGFiled as Pfizer Inc.2025-08-18Yann-Per Lee | pending |
| HEALTH INFORMATION NETWORK WELLNESS PLATFORMFiled as PFIZER INC.2025-08-08DENNIS HANCOCK | pending |
| HEALTH INFORMATION NETWORK WELLNESS PLATFORMG06F 16/90332, G06F 16/24578, G16H 40/67, G16H 40/20, G16H 10/60, G16H 50/30, G16H 50/70, G16H 50/20, G16H 40/63, G06F 16/24539, G06F 16/9035Filed as Pfizer Inc.2025-08-08Dennis HANCOCK | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on PFE
Company overviewEverything on PFE in one place, with the price.SEC filingsWhat PFE's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat PFE's own officers and directors buy and sell.Who owns itEvery manager reporting a position in PFE.Funds holding itWhich funds and ETFs hold PFE, and how big a bet.LobbyingWhat PFE spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on PFE's account, and who they worked for.Federal contractsWhat federal agencies pay PFE.